Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery-Reference-Cited by-同舟云学术

Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery

Published:2015-12 Issue: Volume:220 Page:715-726
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Yang Qi,Parker Christina L.,McCallen Justin D.,Lai Samuel K.

Funder

PhRMA Foundation Predoctoral Fellowship

National Science Foundation

David and Lucile Packard Foundation

National Institutes of Health

UNC

Carolina Center for Cancer Nanotechnology Excellence

Eshelman School of Pharmacy

Lineberger Comprehensive Cancer Center

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference164 articles.

1. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology;Bertrand;Adv. Drug Deliv. Rev.,2014

2. Targeted drug delivery to tumors: myths, reality and possibility;Bae;J. Control. Release,2011

3. Cancer nanomedicines: so many papers and so few drugs!;Venditto;Adv. Drug Deliv. Rev.,2013

4. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation;Stapleton;J. Control. Release,2015

5. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft;Yuan;Cancer Res.,1994

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review;Journal of Controlled Release;2023-07

2. Cell-based relay delivery strategy in biomedical applications;Advanced Drug Delivery Reviews;2023-07

3. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors;Frontiers in Immunology;2022-11-02

4. Chitosan-alginate nanoparticles of cabazitaxel: Design, dual-receptor targeting and efficacy in lung cancer model;International Journal of Biological Macromolecules;2022-11

5. Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma;Pharmaceuticals;2022-05-24